Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.
Tasaki Y, Ito N, Mimura Y, Sugiyama Y, Ogawa R, Shimura T, Nakamura M, Kawakita D, Hamamoto S, Uemura T, Yokota K, Iida M, Odagiri K, Kimura Y, Hotta Y, Komatsu H, Okuda K, Niimi A, Yasui T, Iwasaki S, Morita A, Kataoka H, Takiguchi S, Furukawa-Hibi Y. Tasaki Y, et al. Among authors: mimura y. Asia Pac J Clin Oncol. 2024 Apr 29. doi: 10.1111/ajco.14073. Online ahead of print. Asia Pac J Clin Oncol. 2024. PMID: 38682421
Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
Etani T, Naiki T, Sugiyama Y, Nagai T, Iida K, Noda Y, Shimizu N, Tasaki Y, Mimura Y, Okada T, Banno R, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Etani T, et al. Among authors: mimura y. Oncology. 2020;98(12):876-883. doi: 10.1159/000508923. Epub 2020 Aug 28. Oncology. 2020. PMID: 32862183
Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma.
Tomiyama N, Tasaki Y, Hamamoto S, Sugiyama Y, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Odagiri K, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Furukawa-Hibi Y, Yasui T. Tomiyama N, et al. Among authors: mimura y. Int J Urol. 2023 Sep;30(9):754-761. doi: 10.1111/iju.15198. Epub 2023 May 7. Int J Urol. 2023. PMID: 37150513
Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study.
Tasaki Y, Sugiyama Y, Hamamoto S, Naiki T, Uemura T, Yokota K, Kawakita D, Nakamura M, Ogawa R, Shimura T, Mimura Y, Hotta Y, Odagiri K, Ito N, Iida M, Kimura Y, Komatsu H, Kataoka H, Takiguchi S, Morita A, Iwasaki S, Okuda K, Niimi A, Yasui T, Furukawa-Hibi Y. Tasaki Y, et al. Among authors: mimura y. Cancer Med. 2023 Dec;12(24):21666-21679. doi: 10.1002/cam4.6724. Epub 2023 Nov 21. Cancer Med. 2023. PMID: 37986680 Free PMC article.
Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
Tasaki Y, Hamamoto S, Sugiyama Y, Tomiyama N, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Kubota H, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Yasui T, Kimura K. Tasaki Y, et al. Among authors: mimura y. Int J Urol. 2023 Oct;30(10):866-874. doi: 10.1111/iju.15220. Epub 2023 Jun 6. Int J Urol. 2023. PMID: 37278575
437 results